Robin Reschke, Max-Eder Research Group Leader at National Center for Tumor Diseases (NCT) Heidelberg, shared a post on LinkedIn:
“Dear colleagues
If you have a suitable manuscript for the special issue “Clinical, Immune, and Microbial Markers of Response to Systemic Therapy in Skin Cancer”, or know someone who might be interested, please feel free to share this call or submit your work.
Link.”
Other articles featuring Robin Reschke on OncoDaily.